SLC5A2 and Hypovolemia: It is recommended that streamlined management pathways be established for these patients, centered on the following: 1) Safe medication use: It is imperative to closely monitor and enhance surveillance for the emergence of acute kidney injury, hypovolemia, and hyperkalemia when administering SGLT2 inhibitors in conjunction with NSAIDs or ACEI/ARBs (91).